Financials data is unavailable for this security.
View more
Year on year Glenmark Pharmaceuticals Ltd had net income fall from a gain of 2.97bn to a loss of 15.02bn despite relatively flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 31.29% to 33.49%.
| Gross margin | 65.64% |
|---|---|
| Net profit margin | -8.11% |
| Operating margin | 3.48% |
| Return on assets | -5.64% |
|---|---|
| Return on equity | -11.46% |
| Return on investment | -8.51% |
More ▼
Cash flow in INRView more
In 2024, Glenmark Pharmaceuticals Ltd increased its cash reserves by 14.92%, or 2.15bn. Cash Flow from Investing totalled 45.61bn, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 4.57bn for operations while cash used for financing totalled 39.06bn.
| Cash flow per share | -14.47 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 299.29 |
|---|---|
| Tangible book value per share | 251.39 |
More ▼
Balance sheet in INRView more
| Current ratio | 1.46 |
|---|---|
| Quick ratio | 1.00 |
| Total debt/total equity | 0.2109 |
|---|---|
| Total debt/total capital | 0.1741 |
More ▼
Growth rates in INR
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -1,018.92%. Additionally, five year annualized dividend per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.49% |
|---|---|
| Div growth rate (5 year) | 4.56% |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -71.84 |
More ▼
